🇺🇸 FDA
Patent

US 7906530

1,7-naphthyridine derivatives as p38 MAP kinase inhibitors

granted A61PA61P1/00A61P11/00

Quick answer

US patent 7906530 (1,7-naphthyridine derivatives as p38 MAP kinase inhibitors) held by Laboratories Almirall, S.A. expires Mon Mar 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Laboratories Almirall, S.A.
Grant date
Tue Mar 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61P, A61P1/00, A61P11/00, A61P17/06, A61P19/04